home / stock / nvcn:cc / nvcn:cc news

NVCN:CC News and Press, Neovasc Inc. From 11/08/22

Stock Information
Company Name: Neovasc Inc.
Stock Symbol: NVCN:CC
Market: TSXC
Website: neovasc.com
Menu
NVCN:CC NVCN:CC Quote NVCN:CC Short NVCN:CC News NVCN:CC Articles NVCN:CC Message Board
Get NVCN:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
NVCN:CC - Neovasc Reducer Obtains U.S. Outpatient Reimbursement

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 8, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the Centers for Medicare and Medicaid Services ("CMS") has assigned the Neovasc Reducer™ ("Reduc...
NVCN:CC - Neovasc to Report Third Quarter Financial Results on November 10, 2022

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - October 27, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) will report financial results for the quarter ended September 30, 2022 on Thursday, November 10, 2022. Neovasc's President and Chief Executive Officer Fred Cole...

NVCN:CC - Neovasc Provides Corporate Update Following Clinical Data Release

New Data Presented on the Neovasc Reducer(TM) in Patients With Microvascular Disease Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 20, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced positive clinical data at the Tra...

NVCN:CC - Neovasc to Participate in LSI Europe 2022 Emerging MedTech Summit

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 16, 2022) - Neovasc, Inc.  (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced that its management team will be participating in the LSI Europe 2022 Emerging MedTech Summit in He...
NVCN:CC - Neovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory Angina

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 15, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today commented on the Centers for Medicare and Medicaid Services ("CMS") development of new codes for the di...

NVCN:CC - Neovasc Announces Key Events at TCT 2022

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 8, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced its participation and presence at the Transcatheter Cardiovascular Therapeutics TCT 2022 conference ("TCT"), hos...

NVCN:CC - Neovasc to Participate in H.C. Wainwright 24th Annual Global Investment Conference

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 30, 2022) - Neovasc, Inc. (Neovasc or the Company) (NASDAQ: NVCN) (TSX: NVCN) today announced that its management team will be participating in the H.C. Wainwright 24 th Annual Global Investment Conference...
NVCN:CC - Neovasc Announces Second Quarter Financial Results and Provides Corporate Update

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 11, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the second quarter ended June 30, 2022. Recent Highlights Generated revenues of $818,000, ...

NVCN:CC - Neovasc to Report Second Quarter Financial Results on August 11, 2022

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 28, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter ended June 30, 2022 on Thursday, August 11, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Ch...

NVCN:CC - Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 26, 2022) - Neovasc , Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced the United States Food and Drug Administration ("FDA") has approved a protocol supplement to the COSIRA-II Investig...
Previous 10 Next 10